Search This Blog

Monday, September 3, 2018

Losing Weight the Online Way


Not being able to attend face-to-face meetings doesn’t mean you can’t get the benefits of joining an organized diet group. All you need is an internet connection.
Online diet programs let you sign in for information and motivation at any hour of the day or night.
Participating in a web-based weight-loss program can be helpful in many ways — not just with weight loss, but also with weight-loss maintenance and improving lifestyle habits that might have led to your weight gain.
There are many types of online programs, some from the same companies that offer in-person sessions, and others from successful diet doctors, for instance. So it makes sense to compare choices, especially those with a monthly fee.
Basic offerings tend to include diet information and planning, and goal setting — such as losing inches as well as pounds, and even lowering blood pressure and other cardiovascular disease risk factors. You can often add on bells and whistles like feedback from a diet professional, which may lead to greater success, especially if you’ve lacked motivation in the past.
Some helpful features of online programs include:
  • Personalized calorie counts to lose 1 to 2 pounds a week.
  • Food and exercise diaries.
  • Calorie calculators.
  • Menu plans with a grocery list.
  • Options for special dietary needs.
  • Physical activity plans tailored to your interests.
  • Weekly tips and tricks for motivation and weight loss.
  • Forums or chats for support.
  • Graphs to chart your progress.
Keep in mind that you’ll still need to make the effort to log in, monitor and chart your weight, and keep track of calorie intake and exercise expenditure. But you’ll be able to do this on your schedule and whenever you need a boost of motivation.
More information
The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has detailed information on choosing a diet program with criteria for both online and in-person programs.

Roche Diagnostics partners with U Indianapolis to train, hire directly


Roche Diagnostics aims to build its own talent pipeline for medtech specialists through the University of Indianapolis and the newly created Roche Academy, to funnel students directly into the company.
Through the program, co-developed with the state corporate partnership initiative Ascend Indiana, the university will recruit biology and chemistry students to join the academy, where they will take a Roche-customized curriculum and a hands-on summer internship focused on the necessary life science and engineering skills.
In exchange, students completing the program will receive financial incentives, including a job offer after graduation.
“We have to think differently and more creatively as a company to attract highly skilled talent,” Jack Phillips, president and CEO of Roche Diagnostics, said in a statement. Roche has seen a high demand for qualified biomedical equipment technicians, while the university aims to better align its offerings with industry needs.

“Our supply of skilled workers is not meeting the demand and available talent is often not connecting efficiently with employers who need them,” said Jason Kloth, president and CEO of Ascend Indiana, describing how custom pipeline programs can provide value for the company, institutions and students.
Aiming to produce 20 to 25 technicians annually, Ascend, Roche and UIndy will begin recruitment in October, with the first class estimated to begin work at Roche in 2020. Indianapolis’ Roche Diagnostics serves as the biotech’s North American headquarters, employing more than 4,000 people, while the larger Roche Group is active in over 100 countries with about 94,000 employees worldwide.

Quest for the Perfect Vagina: What To Know About Cosmetic Genital Procedures

Vaginal Rejuvenation and the Quest for the Ideal Vagina

“Vaginal rejuvenation” is really a thing. And companies who promote the use of energy-based devices (primarily lasers) for these unapproved cosmetic genital procedures have now been read the riot act by the US Food and Drug Administration.
Let’s back up. The first reaction for many clinicians is most likely something like: “They’re doing what? Where?
The term “vaginal rejuvenation” is intentionally vague, but it implies that the vagina will be “perkier” afterward—tighter, with better muscle support and renewed vaginal tissue that will enhance both appearance and performance, explained Cheryl Iglesia, MD, director, section of female pelvic surgery, MedStar Washington Hospital Center, Washington, DC. (The medical term for vaginal rejuvenation is “vaginal reconstruction” or “vaginoplasty/perineoplasty,” but the device-makers really loved the term “rejuvenation” and it stuck). Vaginoplasty has even been called “revirgination.”
Other popular procedures include labiaplasty reduction surgery or labia minora plasty, in which surgeons reduce the size of the labia and/or remove loose and unsightly tissue for a more aesthetic look or for functional concerns, such as chafing or irritation of the labia during cycling and other activities.
The American College of Obstetricians and Gynecologists (ACOG) also singled out G-spot amplification, or what others refer to simply as the “O-Shot®.” The O-Shot involves injecting the patient’s own platelet-rich plasma into the general area of the G-spot, purportedly promoting orgasm. ACOG categorically frowns on all cosmetic vaginal procedures, including vaginal rejuvenation, stating that they are neither medically indicated nor proven to be safe and effective, as reflected in their 2007 committee opinion on vaginal rejuvenation and cosmetic vaginal procedures (reaffirmed in 2017).[1] They emphasize that these procedures are not without potential adverse sequelae, such as infection, adhesions, dyspareunia, scarring, and loss of sensation,[1] concerns echoed in the recent FDA safety warning about the safety risks associated with energy-based devices.

Who Performs Cosmetic Genital Procedures?

Make no mistake—women are asking for these procedures, and many practitioners, including ob/gyns, plastic and cosmetic surgeons, and even dermatologists are only too happy to oblige. ACOG does not collect statistics on how many of its members are offering these types of vaginal procedures—so there is no way of knowing how many ob/gyns perform them, Iglesia observes.
Statistics provided by the American Society of Aesthetic Plastic Surgeons[2]suggest that slightly more than one fourth of plastic surgeons offered vaginal and cosmetic genital procedures in 2017, although the number of labiaplasties being performed by plastic surgeons is apparently dropping. Paul Pin, MD, chief of the Division of Plastic Surgery at Baylor University Medical Center in Dallas, Texas, who also teaches plastic surgery at the University of Texas Southwestern Medical School, said that at least in Dallas, more ob/gyns than plastic surgeons are dedicating their entire practices to these procedures—”although looking at the operating room schedules, it seems that a lot of ob/gyns only dabble in this arena,” he added.
The precise number of cosmetic vaginal surgeries performed in the United States is likewise impossible to pin down because they often take place in ambulatory settings, appearing only as a footnote in a patient’s electronic medical record. And health insurance doesn’t cover them. “Most labiaplasties are self-paid, costing between $3000 and $10,000. They are usually done as outpatient procedures, under local anesthesia, and take less than an hour,” Pin explained.
“There is a huge incentive for surgeons to encourage these procedures, especially ob/gyns, who would be lucky to make $3000 for delivering a baby—and that includes all pre- and postnatal care,” he added.

Why Do Women Want These Procedures?

Even with financial inducements to offer these procedures, the question remains: Why do so many women want them? As is true perhaps for all cosmetic surgeries, it comes down to body image and a desire to look different from how they look now. And that desire might follow from having taken a closer look at one’s external genitalia.
In a study published in 2016, Rowen and colleagues[3] found that more than 80% of women surveyed admitted to pubic hair grooming, although it was most common among younger women. “When you groom your pubic hair, you get a better view of what’s underneath,” Iglesia noted—”and a lot of women don’t like what they see.” This was made quite clear by a more recent study that found a high degree of genital dissatisfaction among middle-aged women in the United States.[4] Of note, the frequency of sexual activity was negatively correlated with genital dissatisfaction, an observation that is not surprising to practitioners who have direct experience in women’s sexual health.
“Celebrities and others in the public eye are talking about this,” Iglesia noted, explaining that women have been heard to say, “I’m in a new relationship, so I got my vagina rejuvenated.” Women are also increasingly exposed to images of female genitalia on the Internet and through other sources of pornography. “Everybody wants to have the perfect vagina,” said Sheryl Kingsberg, PhD, chief of behavioral medicine, University Hospitals Cleveland Medical Center in Cleveland, Ohio.
“Laser manufacturers are preying on the desire for a perfect vagina, and their marketing targets every age group with the idea that women can restore tissue to some youthful state and achieve that perfect ‘Barbie doll’ look,” she observed. (By the way, it’s not only girls and women who are falling prey to societal pressure to have perfect genitalia. According to Kingsberg, young boys are exploring a practice called “jelqing,” in which they carry out a series of twists and jerks and all kinds of weird manipulations of their penis in a misguided attempt to turn themselves into porn stars. Needless to say, this can permanently damage the penis.)
Kingsberg, who is also president of the North American Menopause Society (NAMS), does not flat-out condemn the therapeutic potential of laser devices. She points out, for example, that there is some evidence that laser treatment to “resurface” the vagina can significantly improve vaginal atrophy in women who suffer from extreme vaginal dryness. Furthermore, laser treatment offers women a nonhormonal alternative to intravaginal estrogen and gives clinicians another tool to provide relief for postmenopausal women and breast cancer survivors with vaginal atrophy who can’t take estrogen.
“These nonhormonal devices hold tremendous promise—let me make that clear,” Kingsberg said. “I just want to make sure the right research is done and, as the FDA pointed out, that these devices are used only for conditions for which they have shown safety and efficacy. At NAMS, we’re speeding ahead trying to make sure that clinicians are up to date on ethics, standards, and evidence-based treatments,” she emphasized.
Other gynecologists have come to the defense of one technology—–the fractional CO2 laser—maintaining that it isn’t simply cosmetic and shouldn’t be lumped together with the full range of technology and treatments being marketed to women who are dissatisfied with genital appearance.[5] Many gynecologists have found the fractional CO2 laser to be useful in alleviating the vulvovaginal atrophy, dryness, and other symptoms of the genitourinary syndrome of menopause that lead to painful intercourse and an unsatisfying sex life.[5] Although pilot studies are promising,[6] to date, no sham-controlled randomized controlled trial has been conducted to establish the safety and effectiveness of this device.

‘You’re Normal, Just Live With It’

With probably more procedures under his belt than just about anybody else in the United States (800 labiaplasties alone and counting), gynecologist and genital plastic/cosmetic surgeon Michael Goodman, MD, clinical assistant professor of obstetrics and gynecology at California Northstate University School of Medicine, Elk Grove, California, and the author of You Want to Do What? Where? Everything You Ever Wanted to Know About Women’s Genital Plastic & Cosmetic Surgery knows a thing or two about the use—and misuse—of cosmetic vaginal procedures and has strong opinions on who should be offering them and why.
“One of my responsibilities is doing the right things for the right reasons on the right patients,” Goodman said. “And if a woman comes in and says, ‘I’ve got to have a vaginal tightening operation for my boyfriend,’ that is a person I need to counsel and not necessarily just operate on,” he added. On the other hand, Goodman and like-thinking cosmetic genital surgeons feel that if a woman wants a cosmetic vaginal procedure to enhance her self-esteem and possibly her sexual enjoyment, who are they to tell her that she is “normal” and she should just live with a part of her body she doesn’t like, as ACOG recommends its members do? “If a woman goes to see her ob/gyn and says, ‘I’ve always been small and I don’t have a good self-image and would like a breast augmentation,’ or if she says, ‘I’ve always been large and I’d like a breast reduction,’ the ob/gyn will refer her to a plastic surgeon. The same holds true for abdominoplasty and rhinoplasty,” Goodman maintained.
But if a woman says, ‘My labia have always been large and I’m self-conscious about it,’ her ob/gyn might say, ‘You are normal and you should just accept it,” Goodman added. “It’s a combination of paternalism (I don’t think you should do this’) and dismissiveness,” he believes. Goodman also maintains that too few surgeons are trained specifically in these procedures. He often trains other clinicians at his high-volume practice focusing on cosmetic genital procedures and menopausal medicine in Davis, California, and is very involved in the academic worlds of both sexual medicine and plastic surgery. As a leader in this field, Goodman is highly critical of ACOG’s stance to not provide training in the area of cosmetic genital procedures, even though he has offered to hold courses at their annual meetings to teach ob/gyns the right techniques to minimize the risk for unintentional—but avoidable—mistakes. (The same is not true for plastic surgeons, who do offer courses in cosmetic vaginal techniques at many of their meetings, and at least some residents in plastic surgery are now being exposed to these procedures during their training.)
However, as Goodman also observed, “The basics are not just techniques; the basics are understanding what women are saying and understanding their sexuality, and then deciding what procedure would be best for them, in light of their goals,” he emphasized. At the same time, he continued, “Many of my patients say that they know they are normal, but they are still embarrassed and don’t want to make love with the lights on.”
He added, “Female genital plastic surgery is improving their self-image and self-esteem; it can offer functional improvement in terms of being more comfortable in exercise clothes and during certain activities, and can greatly improve sexual enjoyment. All I can say is, what’s wrong with that?”

Sunstar Supports Launch of Chairside Guide to Oral Cancer Prevention, Therapy


Sunstar is proud to announce the launch of Oral Cancer: Prevention and patient management, an FDI World Dental Federation chairside guide for oral health professionals. The guide is supported by Sunstar and aims to mitigate the effects of oral cancer by promoting comprehensive oral cancer screenings as an integral part of routine dental check-ups. It highlights the most common risk factors for oral cancer and underlines the importance of early diagnosis and treatment by providing practical solutions for the care pathway.
The guide was released today at the FDI World Dental Congress in Buenos Aires, Argentina. “FDI recognizes that oral health professionals play an essential role in combatting oral cancer,” said Dr Kathryn Kell, FDI President. “Oral cancer is among the 10 most common cancers worldwide, but oral health professionals can help diminish its effects through early detection and swift treatment action.”
The chairside guide provides oral health professionals with concise, yet comprehensive, information about oral cancer prevention, risk factors and management, and also helps them navigate the clinical examination and diagnosis through a decision tree. It focuses on the most common sites of oral cancer: the tongue, the insides of the cheeks, and the floor of the mouth.
“At Sunstar, we constantly investigate the power of a holistic approach to health to prevent and treat life-threatening conditions as early as possible. This chairside guide is a great example of a tool that supports health professionals in their daily patient screenings. Dental check-ups can be the perfect setting for early detection of several diseases, providing a central prevention role to dental professionals,” said Dr Marzia Massignani, Sr Manager of Scientific Affairs at Sunstar.
Survival rates for oral cancer can be improved through early detection. Therefore, it is essential that oral health professionals such as dentists, dental hygienists, dental therapists and oral health therapists understand the importance of conducting a thorough oral screening examination for malignant and potentially malignant lesions as part of their routine clinical assessments, even in younger populations considered at lower risk for oral cancer. The chairside guide encourages and facilitates the integration of this examination into routine dental check-ups.
“About 500,000 new cases of oral and oropharyngeal cancers are diagnosed annually, three-quarters of which occur in the developing world,” said Dr Ihsane Ben Yahya, FDI Council member and oral cancer expert. “FDI is committed to reducing the oral disease burden and improving oral health outcomes worldwide. By designing an informative tool to prevent,promptly detect and treat oral cancer, we act in line with our mission to lead the world to optimal oral health.”
Oral Cancer: Prevention and patient management is available to consult and download on the Sunstar GUM website [https://professional.sunstargum.com ], and print copies in English and Spanish will be distributed at the FDI World Dental Congress at the Sunstar booth in Buenos Aires, Argentina.

Infant White Matter Tied to Maternal Depression, Anxiety


Variations in the brain white matter microstructure of infants 1 month old were linked to their mothers’ depression and anxiety symptoms during pregnancy, researchers reported.
In a longitudinal study of early-life experience and infant brain development, lower 1-month frontal white matter microstructure was associated with higher prenatal maternal symptoms of depression and anxiety during the third trimester of pregnancy, said Douglas Dean III, PhD, of the University of Wisconsin in Madison, and colleagues in JAMA Pediatrics.
“The developing brain is sensitive to experiences that occur early in life, including during pregnancy,” Dean told MedPage Today. “Our study suggests that maternal experiences with low to moderate levels of depression and anxiety symptoms during pregnancy were associated with variations in the brain’s white matter microstructure, or ‘wiring,’ at 1 month of age.”
“While we cannot detect causal relationships between these processes, these data help us better understand the interplay of experiential events relevant to infant brain measures known to shape emotional and physical well-being later in life.”
The study also suggested that patterns may be different between the sexes, “which may be related to boys and girls having different developmental trajectories and being differentially impacted by certain early life experiences,” Dean added.
Previous studies have linked prenatal exposure to maternal depression and anxiety with poorer outcomes in children, including increased negative reactivity, emotional and behavioral difficulties, lower verbal IQ, and physical health problems, he noted.
Prior research also has shown that prenatal depressive symptoms may be an independent risk factor for depression in adult children, affecting daughters more than sons, observed Rebecca Pearson, PhD, of the University of Bristol in England, who was not involved with the study.
“We’ve seen a female vulnerability to the long-term effects of maternal depression, with female offspring depressed at age 18,” Pearson said in an interview with MedPage Today.
She added that she has also found that depression appears more common among young pregnant women now than in earlier generations. “If it really is going up, we’ve got a generation to follow that could be even more at risk.”
For this study, the researchers studied 101 mother-infant dyads, using a composite of mothers’ depression and anxiety symptoms and infants’ white matter microstructure measured during natural sleep using diffusion tensor imaging and neurite orientation dispersion and density imaging. Diffusion tensor imaging provided metrics of fractional anisotropy, mean diffusivity, axial diffusivity, and radial diffusivity to characterize microstructural integrity of brain tissue. Infant imaging was performed from October 2014 to November 2016.
Mothers completed the 10-item Edinburgh Postnatal Depression Scale and the 20-item State-Trait Anxiety Inventory at 28 and 35 weeks gestation. The mothers reported minimal to moderate levels of depression and anxiety, with 53.5% having minimal depressive symptoms and 41.6% meeting criteria for mild depression. Similarly, the mothers reported low to medium anxiety scores. More than half (53.5%) of the mothers used no medication, 18.8% took pain relief or nonsteroidal drugs, and 11.9% used psychotropics.
The average age of the mothers was about 33, and the average infant age was 33 days. About 91% of the mothers were white; about 53% of the babies were male.
The results showed that lower white matter microstructure at 1 month — decreased neurite density and increased mean, radial, and axial diffusivity — was associated with higher maternal symptoms of prenatal depression and anxiety. There were also differences by sex, with lower fractional anisotropy and neurite density in females and higher fractional anisotropy and neurite density in males exposed to higher levels of maternal depression and anxiety.
“While our work complements existing studies detailing relationships between prenatal maternal depression and anxiety symptoms and offspring brain development, this study highlights that even moderate levels of symptomatology during the prenatal period can influence the infant brain,” Dean said.
This is particularly important because depression and anxiety symptoms are common during pregnancy, and “raises new questions about possible early interventions that may not only help mothers, but could also positively impact the brain development of their infants,” he added.
Limitations of the study, the team noted, included that the design could not assess environmental and genetic effects on infant white matter even as early as 30 days after birth and the cross-sectional data could not examine trajectories of white matter development.
While the findings suggest possible associations between prenatal maternal symptoms and infant white matter, they do not indicate causal relationships, Dean pointed out. And although infants were only 1 month old in this study, postnatal influences had begun to affect development, too.
“It is also important to note that we do not know whether these infant brain associations persist throughout early childhood and beyond,” he added. “While we have conducted brain scans with these same children again at 24 months of age and are just beginning to look at the data, we have not yet been able to complete studies following the same cohort of infants over many years that are critical to answer these types of questions.”
The study was supported by the National Institute of Mental Health and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, both part of the National Institutes of Health.
The rsearchers reported relationships with Corcept Therapeutics and owning patents related to promoter sequences for corticotropin-releasing factor.
  • Reviewed by Dori F. Zaleznik, MD Associate Clinical Professor of Medicine (Retired), Harvard Medical School, Boston and Dorothy Caputo, MA, BSN, RN, Nurse Planner
LAST UPDATED 

‘I Almost Shot Myself in the Head Until’ Family and Friends Intervened


“Once your kids are older, please encourage them to get help if they start with your symptoms,” Dr. K soberly instructed me recently. This came after a roller-coaster ride over the past year to sort out and treat my increasing and overwhelming desire to shoot myself in the head.
Although the cause of suicidality varies from person to person, this is my story.
I’m a happily married 59-year-old general practitioner. Both of our adult children have completed college and are gainfully employed. There was no one I wanted to hurt with my death.
For the longest time, I thought I had allergic conjunctivitis. As it turned out, once the crying and fighting the urge to cry resolved with Effexor, my conjunctiva cleared-up. Frankly, I have always questioned the validity of fibromyalgia, until I started with symptoms. Then, just like my “allergic conjunctivitis,” Effexor also gave me relief of my chronic upper back and neck trigger points, fatigue, sleep, memory, and mood issues … so much for my own diagnostic skills.
Unfortunately, there was no real change in my suicidality with Effexor. Only the frequency lessened to a few times a day.
I knew I was depressed, really depressed. I was ignoring and fighting these feelings ever since I was a young adult because there was no reason for my sadness. I was embarrassed because my childhood was so great. I felt I never suffered enough to become depressed; I felt like a spoiled brat, crying for no reason.
During my neurosurgical rotation as a surgical resident, I felt differently when the ER paged me regarding a patient with a self-inflicted gunshot wound to the head. I lacked the profound sadness that I had for other patients that died by any other means. There was a morbid sense of solace and closure for these predominantly twenty-something males. Neither the family chaos in the waiting room nor lack of an organ donor card really touched my heart. In retrospect, I was callous and selfish.
My maternal great-grandfather took his life with his shotgun loaded with a slug. But not before telling his son (my grandfather) his plans. He was an octogenarian, and the DMV sent him a notice that he could no longer drive. My grandfather did nothing to prevent it. In fact, he shared the story with me as a young teenager. He told me that he planned the same, “when the time came.”
Zeus is a three-year-old Belgian Malinois, trained to be a service dog for Leysh, one of the medical assistants at our clinic. He has been with us since he was a puppy. A couple of years ago, I was contemplating shooting myself. I had a Sig Sauer P238 at work. It was a bad day, a terrible day. We have always joked that Zeus has ADHD – it’s a Mal thing. So, when he came into my office and placed his head on my lap, looking up at me with a concerned expression which I have never seen before, I still thought he just wanted to play, but he didn’t move for over 15 minutes. Only when my bad thought started to subside as I was petting his head, Zeus left, only to return with his favorite bone and placed it in my lap. Then he brought and put his favorite toy at my feet. He finally laid down at my feet, keeping me company. Watching over me.
It was a few weeks later when Leysh got into trouble with me regarding a non-work-related issue. She is like a daughter to my wife and me. We argued, then I asked her to promise never again to do what she did. She said, “I can’t promise that, but will promise to try … if you promise me something.” I asked her what it was. “Get rid of Megan’s handgun and never get another one.” She broke down in tears and said, “Because I don’t want you to shoot yourself.” In tears, I assured her I was only sad and would never shoot myself – I agreed to her terms.
How Zeus and Leysh knew, I’ll never know, but I needed to get help.
That phone call was the first time I ever told anyone about my suicidality. I was so embarrassed and felt “broken.” Dr. K’s receptionist told me that his next appointment for a new patient was 6 months out. I asked if I could leave him a message, and she said, “Yes.” On the message, I mentioned that I’m a 58-year old physician with strong suicidal ideation. The receptionist called back the next day and made me an appointment for 3 weeks, which was still quite a stretch. For being a simple task, it was the hardest call I have made in years. At the same time, I felt hope. It was the longest 3 weeks.
Dr. K is a portly 78-year-old wizard of psychiatry. His clinic is an old, dimly lit converted home furnished with tattered swap-meet-caliber furniture. Maybe even a borderline hoarder. Every waiting room chair was filled with disheveled patients with flat affects and overt psychiatric pathology. Patients were also standing outside smoking partially smoked cigarettes they found nearby. I felt out of place and comfortable at the same time.
His endearing compassionate concern was remarkable. He had tears welling up as I shared my medical history. Dr. K assured me that my suicidality was secondary to severe major depressive disorder and started me on Effexor.
The following week I told him with enthusiasm that my red, irritated eye and other psychosomatic symptoms resolved. I also shared that my wife and I have been together since high school. Together we have tackled a lot of stressful events; almost losing our newborn son with hereditary nephrogenic diabetes insipidus and losing our home in the California cedar fire to name just a few. So, Jaleh knew what to do. She removed all firearms from the house and did everything she could to decrease any external stressors that came our way.
Over the next few months, I slowly increased my dosage of Effexor. Unfortunately, the side effects made it hard to be compliant, so Dr. K switched me to Wellbutrin which had no adverse issues, but I had a relapse of my depression and suicidality. It came back with a vengeance.
Up to that time, I was running from the urge to end my life, then with this relapse, I couldn’t run any longer, so I started to prepare and plan my death. Dr. K restarted the Effexor and kept me on Wellbutrin. Additionally, he wanted to hospitalize me for 2 weeks. Having a private practice, I couldn’t be away for that long. What would be different in treatment besides preventing me from killing myself? Dr. K said, “That’s exactly what I want to prevent.” We finally agreed on a promise not to kill myself, but if I needed to break the promise, I would call him. I also agreed to a 3-day stay in the hospital for ECT treatment in the near future.
The following week, Dr. K wanted to first start lithium before ECT. I always thought lithium was only for bipolar treatment; I was wrong. 5 days later, it was like someone turned the switch off in my brain for suicidality. A switch which has been on for my entire adult life. Just as I wouldn’t jump into a pit of rattlesnakes, I now would never put the muzzle of a loaded pistol against my temporal bone and pull the trigger.
A couple of weeks later, Dr. K asked me what kept me from taking my own life. I told him it was my four girls and a dog; my wife, my daughter, Leysh (like a daughter), French (like family) who also works with me, and Zeus who had canine instincts to keep me safe.
There is no doubt, Dr. K saved my life. With his advanced age, I needed to know when he planned to retire. He said he already has plans once he cures all his patients. But on a serious note, the wait time to see a psychiatrist is unacceptable. We need to groom a lot more Dr. Ks because I suspect my story is the tip of a curable iceberg that is melting too fast.
Yes, I’m still embarrassed about my diagnosis and the fact I remain on Effexor, Wellbutrin, and lithium. To date, only a handful of people know this dark side of me. Having equivocal thoughts about writing this article, I thought about the fact that the rate of physician suicides is highest of any profession and exceeds that of our military, yet we don’t hear much about this “epidemic” in the United States. And I don’t want to be embarrassed anymore – maybe this will help. Perhaps it helps to remove the stigma when the time comes to discuss the genetic component of suicidality with my kids. Either way, a long life of embarrassment will suit my family and me well.
Thomas L. Watson, MD, is a physician who lives and practices in San Diego. Watson attended Centro De Estudios Universitarios Xochicalco in Mexico and is certified by the American Board of Urgent Care Medicine.

Lonza Gives 1st Glimpse of Next-Gen Endotoxin Detection at Confab


Lonza will reveal its next-generation endotoxin automation solution, PyroTec™ Pro Robotic Solution at the Parenteral Drug Association (PDA) Global Conference on Pharmaceutical Microbiology from 15-16 October, in Bethesda, MD (USA). At Booth #308 Lonza experts will demonstrate how the company’s instruments, reagents and software are integrated into the robotic platform, providing a fully automated workflow solution.
Lonza’s Next-Generation Robotic Solution for Endotoxin Detection
Consistent with the FDA’s Process Analytical Technology (PAT) initiative, Lonza is introducing a new generation of automated endotoxin detection driven by its market leading WinKQCL™ Endotoxin Detection Software.
Attendees of the PDA can see Lonza’s PyroTec™ Pro Robotic Solution for endotoxin testing and talk directly to Lonza experts about the innovations in the new WinKQCL™ Software. A few of the highlighted features include:
  • Adapting to changes: WinKQCL™ Software can generate robotic scripts and adapt to changing sample dilution requirements.
  • Offering a ‘walk-away’ solution: The WinKQCL™ Software can control the procedure from start to finish.
  • Saving time and reducing risk: WinKQCL™ Software can import sample test worklists from a sample management system and export the results back out to the same system, preventing transcription errors and saving time over manually entering data.
Poster: The Automation of Endotoxin Testing
During the PDA Endotoxins Workshop that follows the conference on 17-18 October, Lonza will present a new poster demonstrating how automated endotoxin testing can reduce the potential for human error substantially, enhancing the accuracy, reliability and traceability of results.
The presentation will also show how laboratories can maximize their return on investment through the time and cost savings provided by automated endotoxin testing technology.
Titled ‘The Automation of Endotoxin Testing: Streamlining Your QC Testing with Automated Endotoxin Testing and Process Optimization,’ the poster will be presented by Robert Porzio, Product Manager at Lonza. He will explain how Lonza’s WinKQCL™ Endotoxin Automation Software Module can revolutionize the way endotoxin testing is being performed, allowing for an overall enhancement of lab efficiency and productivity. In addition to this presentation, Lonza experts will be available at Booth #7 to consult with analysts on how automated endotoxin testing technology can help them streamline their QC testing processes and better monitor endotoxin contamination.
PyroTec™ Pro Robotic Solution will be demonstrated:
  • On 15 October, from 11:45 am-7:00 pm
  • On 16 October, from 9:45 am-4:00 pm
  • At Booth #308, in the Exhibit Area of the Bethesda North Marriott Hotel & Conference Center
The poster presentation will be held:
  • On 17 and 18 October, from 3:30-4:00 pm
  • In the Exhibit Area of the Bethesda North Marriott Hotel & Conference Center
  • Lonza experts will be available at Booth #7.
Further information can be found at Lonza Booth #308 at the PDA Global Conference on Pharmaceutical Microbiology 15-16 October or at Booth #7 during the PDA Endotoxins Workshop 17-18 October.